selective, and rapid transformation of primary amines and diamines to isothiocyanates and cyclic thioureas is disclosed. As opposed to established approaches that employ toxic or volatile electrophilic liquids and require reaction control (i.e., slow addition, cooling), this protocol utilizes the bench-stable, solid reagent (Me4N)SCF3 at room temperature. The method is characterized by operational simplicity
Reaction of Thiocarbonyl Fluoride Generated from Difluorocarbene with Amines
作者:Jiao Yu、Jin-Hong Lin、Ji-Chang Xiao
DOI:10.1002/anie.201710186
日期:2017.12.22
The reaction of thiocarbonyl fluoride, generated from difluorocarbene, with various amines under mild conditions is described. Secondary amines, primary amines, and o‐phenylenediamines are converted to thiocarbamoyl fluorides, isothiocyanates, and difluoromethylthiolated heterocycles, respectively. Thiocarbamoyl fluorides were further transformed into trifluoromethylated amines by using a one‐pot process
Abstract A number of alkyl, aryl and bifunctional isothiocyanates are obtained in moderate to high yields (41–94%) in a two-step, one-pot reaction of the parent primary amines or their salts with carbondisulfide, followed by reaction of the thus formed dithiocarbamates with T3P® (propane phosphonic acid anhydride) as a new and efficient desulfurating agent. A number of alkyl, aryl and bifunctional isothiocyanates
Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation
seizure test and MTL-1 excellently protected animals against PTZ induced seizure at the dose of 30 mg/kg. MTL-1 also indicates long duration of action in time course study and displayed significant seizure protection up to 6 h of drug administration. Further, the anti-epileptogenic effect of MTL-1 has been examined in PTZ induced chronic model of epilepsy. The results indicated that MTL-1 had a significant
Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1
作者:Celeste N. Alverez、Jung-Eun Park、Kiran S. Toti、Yangliu Xia、Kristopher W. Krausz、Ganesha Rai、Jeong K. Bang、Frank J. Gonzalez、Kenneth A. Jacobson、Kyung S. Lee
DOI:10.1021/acs.jmedchem.0c01669
日期:2020.11.25
As a mitotic-specific target widely deregulated in various human cancers, polo-likekinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catalytic domain inhibitors were tested in preclinical and clinical studies, their efficacies are limited by dose-limiting cytotoxicity, mainly from off-target cross reactivity. The C-terminal noncatalytic polo-box
作为在各种人类癌症中广泛失调的有丝分裂特异性靶标,polo 样激酶 1 (Plk1) 已被广泛探索用于抗癌活性和药物发现。尽管在临床前和临床研究中测试了多种催化结构域抑制剂,但它们的功效受到剂量限制性细胞毒性的限制,主要来自脱靶交叉反应。 Plk1 的 C 端非催化 polo-box 结构域 (PBD) 已成为产生新的蛋白质-蛋白质相互作用抑制剂的有吸引力的靶标。在这里,我们鉴定了一种 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3 -a ]quinazolin-5(1 H )-one 支架,可有效抑制 Plk1 PBD,但不能抑制其相关的 Plk2和 Plk3 PBD。结构-活性关系研究发现多种抑制剂的抑制活性比之前表征的 Plk1 PBD 特异性磷酸肽 PLHSpT ( K d ∼ 450 nM) 高 ≥10 倍。此外, S-甲基前药有效抑制有丝分裂进